BRVO 4 mg Dose Triamcinolone Acetonide [clinicaltrials_resource:NCT00105027/group/B6]
Treatment administered at baseline. At each 4-month visit during follow-up, the investigator assessed whether persistent or recurrent macular edema was present that warranted retreatment with the 4 mg dose. Patients and investigators were masked to the triamcinolone acetonide dose used (1 mg or 4 mg).
group [clinicaltrials_vocabulary:group]
NCT00105027 measurement [clinicaltrials_resource:NCT00105027/measurement/2c82b2944df08cba75827e1bf0a7cfaa]NCT00105027 measurement [clinicaltrials_resource:NCT00105027/measurement/85e1ba76d22a241203eb13501b2e8dfc]NCT00105027 measurement [clinicaltrials_resource:NCT00105027/measurement/9d1badfdc450fbfed9d6051f70e20704]NCT00105027 measurement [clinicaltrials_resource:NCT00105027/measurement/cab36b870fa6338520c500fccfb2bfed]NCT00105027 measurement [clinicaltrials_resource:NCT00105027/measurement/e32d821af2b74ac82fbf25729af1a7e9]NCT00105027 measurement [clinicaltrials_resource:NCT00105027/measurement/ebe8b17d9b0fbaeea82dc7b723e5c9df]NCT00105027 measurement [clinicaltrials_resource:NCT00105027/measurement/f2978ee9c8e50c0b4dc45b58a4850b91]
group id [clinicaltrials_vocabulary:group-id]
BRVO 4 mg Dose Triamcinolone Acetonide [clinicaltrials_resource:NCT00105027/group/B6]
Treatment administered at baseline. At each 4-month visit during follow-up, the investigator assessed whether persistent or recurrent macular edema was present that warranted retreatment with the 4 mg dose. Patients and investigators were masked to the triamcinolone acetonide dose used (1 mg or 4 mg).
Bio2RDF identifier
NCT00105027/group/B6
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00105027/group/B6
group id [clinicaltrials_vocabulary:group-id]
description
Treatment administered at base ...... nide dose used (1 mg or 4 mg).
@en
identifier
clinicaltrials_resource:NCT00105027/group/B6
title
BRVO 4 mg Dose Triamcinolone Acetonide
@en
type
label
BRVO 4 mg Dose Triamcinolone Acetonide [clinicaltrials_resource:NCT00105027/group/B6]
@en